ANTIBODIES AGAINST ILT2 AND USES THEREOF

To provide a monoclonal antibody or an antigen binding portion thereof that binds to a human ILT2 epitope within the sequence of human leukocyte immunoglobulin-like receptor subfamily B member 1 (ILT2), as well as a pharmaceutical composition and method for producing same.SOLUTION: Provided is a mon...

Full description

Saved in:
Bibliographic Details
Main Authors AVIDOR SHULMAN, ANNA FRIDMAN-DROR, MOTTI HAKIM, TSURI PERETZ, ILANA MANDEL, DROR ALISHEKEVITZ, YAIR SAPIR, ILANA GOLDSHTEIN, TEHILA BEN-MOSHE, DANA HAVES ZIV
Format Patent
LanguageEnglish
Japanese
Published 26.07.2023
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:To provide a monoclonal antibody or an antigen binding portion thereof that binds to a human ILT2 epitope within the sequence of human leukocyte immunoglobulin-like receptor subfamily B member 1 (ILT2), as well as a pharmaceutical composition and method for producing same.SOLUTION: Provided is a monoclonal antibody or antigen-binding fragment that has three heavy chain CDRs (CDR-H) and three light chain CDRs (CDR-L) of specific sequences and that binds to ILT2 and inhibits ILT2-mediated immune cell suppression.SELECTED DRAWING: None 【課題】ヒト白血球免疫グロブリン様受容体サブファミリーＢメンバー１（ＩＬＴ２）の配列内のヒトＩＬＴ２エピトープに結合する、モノクローナル抗体またはその抗原結合性部分、ならびにそれを含む医薬組成物およびそれを生成する方法を提供する。【解決手段】特定の配列からなる３つの重鎖ＣＤＲ（ＣＤＲ－Ｈ）および３つの軽鎖ＣＤＲ（ＣＤＲ－Ｌ）を有し、ＩＬＴ２に結合しＩＬＴ２媒介免疫細胞抑制を阻害する、モノクローナル抗体または抗原結合性断片を提供する。【選択図】なし
Bibliography:Application Number: JP20230081165